Form 4: Athira Pharma's Chief Medical Officer, Javier San Martin, Acquires Stock Options and Restricted Stock Units
SEC Form 4 Filing
Javier San Martin, Chief Medical Officer of Athira Pharma, acquired 140,000 stock options and 140,000 restricted stock units on October 1, 2024, according to a recent SEC filing.
Summary
- On October 1, 2024, Javier San Martin, the Chief Medical Officer of Athira Pharma, acquired 140,000 restricted stock units (RSUs) and 140,000 stock options.
- The RSUs will vest in three equal installments on December 31, 2024, June 30, 2025, and December 31, 2025, contingent upon continued service with the company.
- Similarly, the stock options will vest in three equal installments on the same dates, also contingent upon continued service.
- The exercise price for the stock options is $0.4499.
- Following these transactions, San Martin directly owns 140,000 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The grant of stock options and RSUs to a key executive suggests confidence in the company's future. The vesting schedule incentivizes long-term commitment.
Positives
- The acquisition of stock options and restricted stock units by a key executive like the Chief Medical Officer can be seen as a positive sign, indicating confidence in the company's future performance.
- The vesting schedule incentivizes continued service and commitment from the executive.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedule suggests an expectation of continued service and contribution from the executive.
Industry Context
Stock option and RSU grants are common compensation practices in the pharmaceutical industry to incentivize and retain key executives. These grants align the executive's interests with those of the shareholders.
Comparison to Industry Standards
- Stock option and RSU grants are a standard component of executive compensation packages in the biotech and pharmaceutical industries.
- Companies like Biogen, Amgen, and Gilead Sciences also utilize similar equity-based compensation to align executive incentives with shareholder value.
- The vesting schedules and exercise prices are generally structured to incentivize long-term performance and retention.
Stakeholder Impact
- Shareholders may view the equity grants as a positive sign, aligning management's interests with their own.
- Employees may see this as a positive indicator of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 10/01/2024 | Date of transaction: Javier San Martin acquired restricted stock units and stock options. |
| 12/31/2024 | First vesting date for one-third of the RSUs and stock options. |
| 06/30/2025 | Second vesting date for one-third of the RSUs and stock options. |
| 12/31/2025 | Final vesting date for one-third of the RSUs and stock options. |
| 09/30/2034 | Expiration date of the stock options. |
| 10/03/2024 | Date of the form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.